Tag: SGLT-2 inhibitors

SGLT-2 inhibitors cut risk of death in diabetics, data shows

by Selina McKee | Mar 13, 2018 | News | 0

AstraZeneca has unveiled findings of a new analysis of data from the CVD-REAL study, showing a significant cut in the risk of all-cause death (ACD) in patients with type II diabetes taking SGLT-2 inhibitors.

AZ unveils new data on Farxiga backing earlier use

by Selina McKee | Jun 13, 2017 | News | 0

AstraZeneca has presented findings from a real-world analysis potentially supporting earlier and wider use of the SGLT-2 inhibitor class of drugs in the diabetes treatment pathway.